Friday, December 17, 2021 1:04:56 PM
Scripts for week ending December 10, 2021
Overall drug TRx: +0.3% w/w
Vascepa
TRx 83,075; +1.3% (+1,091) w/w; -5.7% y/y
NRx 37,688; +4.9% (+1,763) w/w; -4.6% y/y
Ref 45,387; -1.5% (-672) w/w; -6.5% y/y
Lovaza (Generic & Brand)
TRx 65,758; +0.7% (+475) w/w; +0.5% y/y
NRx 32,730; +0.8% (+268) w/w; -0.4% y/y
Ref 33,029; +0.6% (+207) w/w; +1.4% y/y
Generic Vascepa
TRx 23,900; +2.1% (+489) w/w; As % of total V: 22.3%
NRx 13,400; +4.5% (+571) w/w; As % of total V: 26.2%
Ref 10,500; -0.8% (-82) w/w; As % of total V: 18.8%
Generic Vascepa by Manufacturer
Hikma - TRx 13,470 (-134); Generic share 55.8%; Total V share 12.5%
Hikma - TRx 10,565 (+624); Generic share 44.2%; Total V share 9.9%
Vascepa + Generic Vascepa
TRx 106,975; +1.5% (+1,581) w/w
NRx 51,088; +4.8% (+2,334) w/w
Ref 55,887; -1.3% (-754) w/w
Overall drug TRx: +0.3% w/w
Vascepa
TRx 83,075; +1.3% (+1,091) w/w; -5.7% y/y
NRx 37,688; +4.9% (+1,763) w/w; -4.6% y/y
Ref 45,387; -1.5% (-672) w/w; -6.5% y/y
Lovaza (Generic & Brand)
TRx 65,758; +0.7% (+475) w/w; +0.5% y/y
NRx 32,730; +0.8% (+268) w/w; -0.4% y/y
Ref 33,029; +0.6% (+207) w/w; +1.4% y/y
Generic Vascepa
TRx 23,900; +2.1% (+489) w/w; As % of total V: 22.3%
NRx 13,400; +4.5% (+571) w/w; As % of total V: 26.2%
Ref 10,500; -0.8% (-82) w/w; As % of total V: 18.8%
Generic Vascepa by Manufacturer
Hikma - TRx 13,470 (-134); Generic share 55.8%; Total V share 12.5%
Hikma - TRx 10,565 (+624); Generic share 44.2%; Total V share 9.9%
Vascepa + Generic Vascepa
TRx 106,975; +1.5% (+1,581) w/w
NRx 51,088; +4.8% (+2,334) w/w
Ref 55,887; -1.3% (-754) w/w
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
